Wee1 Inhibitor

p38α-IN-9 (Compound 2015) is a p38α inhibitor and blocks p38α’s enzymatic activity with an IC₅₀ lower than 20 nM. p38α-IN-9 inhibits MK2^T334 phosphorylation. p38α-IN-9 activates Cdc25b and Cdc25c and simultaneously inactivates Wee1, leading to mitotic catastrophe, aneuploidy or polyploidy and DNA damage. p38α-IN-9 Inhibits colorectal cancer (CRC) metastasis.

PD0166285 dihydrochloride, a substrate of P-gp, is a WEE1 inhibitor and a weak Myt1 inhibitor with IC₅₀ values of 24 and 72 nM, respectively. PD0166285 dihydrochloride exhibits an IC₅₀ of 3.433 μM for Chk1.

WEE1-IN-8 (Compound 55) is a selective WEE1 inhibitor, with an IC₅₀ of 0.98 nM. WEE1-IN-8 (Compound 55) can be used for the research of Pancreatic cancer, Ovarian cancer, Colorectal cancer, Uterine serous carcinoma, etc.

AZD1775-C3-NH2 is a Target Protein Ligand-Linker Conjugate that contains a target protein ligand and a PROTAC linker, and can recruit E3 ligases. AZD1775-C3-NH2 can be used for the synthesis of Pomalidomide-C3-adavosertib (HY-133618).

Adavosertib-C3-NH-Boc is a Target Protein Ligand-Linker Conjugate that incorporates a ligand for Wee1 (HY-10993) and a PROTAC linker (HY-W011561), which recruits E3 ligases. Adavosertib-C3-NH-Boc can be used for synthesis of PROTAC Pomalidomide-C3-adavosertib (HY-133618).

PKMYT1-IN-11 (Example 1) is a PKMYT1 inhibitor with an IC₅₀ of 4.49 nM. PKMYT1-IN-11 inhibits the proliferation of HCC1569 cells. When combined with Gemcitabine (HY-17026), PKMYT1-IN-11 shows a significant anti-tumor effect in the OVCAR3 xenograft mouse model. PKMYT1-IN-11 can be used for the study of various cancers such as breast cancer and ovarian cancer.

CJM061 is a WEE1 kinase inhibitor with a target IC₅₀ of 2.8 nM. CJM061 acts as a sensitizer and exhibits synergistic effects with Cisplatin (HY-17394) in medulloblastoma cells. CJM061 can be used for the research of medulloblastoma.

WEE1-IN-11 (Compound 13) is a potent CDK2 inhibitor with an IC₅₀ of 2.0 nM. WEE1-IN-11 inhibits NCI–H446, A427, OVCAR3, C33A,and WiDr cells with IC₅₀s of 93.9, 34.5, 86.7, 23.1, and 85 nM, respectively.

WEE1-IN-4 (Standard) is the analytical standard of WEE1-IN-4 (HY-108343). This product is intended for research and analytical applications. WEE1-IN-4 (Compound 15) is a potent checkpoint Wee1 K_inase inhibitor with an IC₅₀ of 0.011 μM. Wee1 inhibitors can abrogate the G2/M checkpoint.

Sirusertib (WEE1A&Myt1-IN-1) is a dual Wee1A/Myt1 inhibitor, with an IC₅₀ of ≤10 nM against Wee1A and ≤20 nM against Myt1. Sirusertib is applicable for cancer-related research.

lunresertib (Standard) is the analytical standard of lunresertib (HY-145817A). This product is intended for research and analytical applications. lunresertib (RP-6306) is a potent, selective and orally active PKMYT1 inhibitor with an IC₅₀ of 14 nM. lunresertib shows a high degree of selectivity over other K_inases in cellular binding assays. lunresertib shows anticancer effects.

PKMYT1-IN-7 (compound 7) is an orally active PKMYT1 inhibitor with IC₅₀ values of 1.6 nM and 0.06 μM against of PKMYT1 and pCDK1, respectively. PKMYT1-IN-7 suppresses the phosphorylation of CDK1 at T14 and Y15. PKMYT1-IN-7 shows anticancer activity both < and <.